Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
about
HIV-1 neutralizing antibodies: understanding nature's pathwaysStructure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivityStructural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry InhibitorsVaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesignThe Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal ApplicationsHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesFunctional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Closing the door to human immunodeficiency virus.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining regionGenetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domainDifferential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection.Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.Back to the future: covalent epitope-based HIV vaccine development.Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in ChinaEarly short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques.Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationBroadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.The development of CD4 binding site antibodies during HIV-1 infection.Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and BioinformaticsRhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
P2860
Q27000480-96EA4437-F3B7-4F31-9927-4643B1ACB677Q27660384-6BF7A94F-C529-4467-8F61-29B674487055Q27663293-0703DD9E-38A5-4C57-A415-4808252ADB81Q27666407-339D91BF-9E12-4BC9-B617-133D73089CABQ27675468-D533EF7F-F4D4-43C4-9BE6-FA3300FE5583Q27678493-994DC7EE-B0BC-40B7-8081-B19B57B9347AQ27681806-DA728FC7-E7A7-4AE8-97FF-671D6658B132Q28546014-D55D63EA-8ADD-454B-ABFB-DDC1826D2F80Q28602877-CD31E0DF-9547-4A22-B4F8-6CDB6C416F40Q28743199-FD6A9B44-2475-4AA5-B603-52192139E124Q30428089-B97F6153-8AF3-4554-99F1-E6E3A3D0A245Q31132248-A4456C07-7A3B-4AE8-A444-9ED2CAA7EC02Q33676600-A11D6AAB-C6D9-4E0D-9936-BCF195675539Q33719511-774BC902-0E28-4A52-9C6E-780C5A1638C9Q33826682-02560179-66F2-4D70-B673-363488A618DDQ34034659-6EA1DE04-D436-424C-9775-2349314AB966Q34075820-168E3CBD-F6AF-4595-9D91-0971C25CD9C9Q34133551-17A8B9A8-6DD4-4F1A-B668-C5EF60405461Q34170655-CBF38236-FD14-4496-9D34-A4A12EBDF061Q34230556-56D31D49-B8B4-4098-9954-C2E02C4446BBQ34239109-31EF5D62-3380-4462-8B30-8806AA150693Q34397758-790A6766-8E42-44D7-A030-05057E90D0C0Q34551010-4311D93E-9689-4268-BB3A-5636FDA34EF4Q34594978-0CF0EB9D-11DF-4850-A0D0-3DAD576ECAC2Q34597300-D2497C65-A0FB-493B-9ED7-F03E0A4CF367Q34800408-41E37FF0-0E2A-47A8-AC50-3605711B7F1FQ35069126-C638FA36-407B-460E-AF54-E291D2B1445BQ35192782-7F492704-9488-4F08-8685-26FBFC180DA7Q35196530-C1F97470-B077-49A9-AEED-8A567EDD2D45Q35603504-D54F3905-1A87-417A-A137-2CB8567A98ECQ35644971-2B6744AF-B179-46B5-B18F-0EFA44BFAD55Q35914292-02B11FFF-9E6B-4A28-A7AD-7014608CE780Q35943521-D0A2B768-C701-48BC-8CB1-FD481251C468Q35985519-ED2265A4-D70E-4130-8BB5-F2B2828FD921Q36127736-481313AF-279E-4210-AAFC-93C7AB3BEAA4Q36155396-E1575679-1BA5-47A7-B4D8-8D6AA58F5B11Q36231944-82E1AB80-E5F7-4615-84FD-218DA3E8742EQ36245216-C7C52ED4-A204-4A89-83D6-462D1405B705Q36246315-374761AC-03A2-4DAA-9A7B-4CF30E7AF133Q36276274-534821DC-D36A-4391-BB87-BED19856673F
P2860
Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@en
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@nl
type
label
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@en
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@nl
prefLabel
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@en
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@nl
P2093
P2860
P356
P1433
P1476
Mechanism of human immunodefic ...... ts the site of CD4 attachment.
@en
P2093
Peter D Kwong
Richard T Wyatt
Sijy O'Dell
Tongqing Zhou
Xueling Wu
P2860
P304
10892-10907
P356
10.1128/JVI.01142-09
P407
P577
2009-08-19T00:00:00Z